Drugs / Abiprubart
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04497662 | Oct 2019 → Jan 2021 | — | Kiniksa Pharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06531395 | Jul 2024 → Mar 2025 | Sjogren syndrome | Kiniksa Pharmaceuticals International, plc | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05198310 | Dec 2021 → Feb 2024 | rheumatoid arthritis | Kiniksa Pharmaceuticals, Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2024-01-04 | Kiniksa Pharmaceuticals International, plc | Results Kiniksa Pharmaceuticals Provides Corporate Update kiniksa.com ↗
Despite a high placebo response rate, the 5 mg/kg weekly dose level in Cohort 3 achieved statistical significance, but the 5 mg/kg biweekly dose level did not. |
| 2021-05-04 | Kiniksa Pharmaceuticals International, plc | Results Kiniksa Reports First Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity kiniksa.com ↗
Kiniksa announced final data today from the KPL-404 Phase 1 clinical trial in healthy volunteers. |
| 2021-05-04 | Kiniksa Pharmaceuticals International, plc | Results Kiniksa Announces Positive Final Data from Phase 1 Trial of KPL-404 kiniksa.com ↗
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced positive final data from the Phase 1 clinical trial of KPL-404 in healthy volunteers. |
| 2020-11-30 | Kiniksa Pharmaceuticals International, plc | Results Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404 kiniksa.com ↗
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunological pathways across a spectrum of diseases, today announced preliminary data from the Phase 1 clinical trial of KPL-404 in healthy volunteers. |
| 2019-04-08 | Kiniksa Pharmaceuticals International, plc | Results Kiniksa to Present KPL-404 Preclinical Data at the Keystone Symposia on Antibodies as Drugs kiniksa.com ↗
KPL-404, a CD40 antagonist, blocked antigen-specific antibody responses in an in vivo NHP model and demonstrated strong PK/PD correlation |
All press releases naming this drug 7 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Abiprubart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06531395 ↗ |
| Known as | KPL-404 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05198310 ↗ |
| Modality | Monoclonal antibody | “humanized IgG4 monoclonal antibody” NCT04497662 ↗ |
| Route | Intravenous | “single ascending intravenous (IV) and subcutaneous (SC) doses of KPL-404” NCT04497662 ↗ |
| Route | Subcutaneous | “single ascending intravenous (IV) and subcutaneous (SC) doses of KPL-404” NCT04497662 ↗ |